Fingolimod (Gilenya®)


Indications for Prior Authorization:

  • Relapsing remitting multiple sclerosis (RRMS)

Patients must meet the following criteria for the indications above:

  • This drug may not be used in combination with each other or any other disease modifying therapy for MS, either oral or injectable

This medication is not approvable for the following condition(s):

  • Any condition not listed above does not meet WHA criteria for approval


  • fingolimod 0.5 mg twice a day


  • Initial approval for one year
  • Renew for one year if patient has clinical response


Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.